Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3

Active, not recruiting

Conditions: Ovarian Mucinous Adenocarcinoma
Stage IIA Fallopian Tube Cancer AJCC v6 and v7
Stage IIIB Fallopian Tube Cancer AJCC v7
Ovarian Clear Cell Adenocarcinofibroma
Ovarian Serous Adenocarcinoma
Ovarian Undifferentiated Carcinoma
Stage IIA Ovarian Cancer AJCC V6 and v7
Stage IIC Fallopian Tube Cancer AJCC v6 and v7
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Paclitaxel
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2010-07-22

Last Posted Date: 2025-01-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 692

Registration Number: NCT01167712

Locations: 🇺🇸
Mid Dakota Clinic, Bismarck, North Dakota, United States
🇺🇸
Doctors Hospital, Columbus, Ohio, United States
🇺🇸
Miami Valley Hospital, Dayton, Ohio, United States

and more 562 locations

Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Phase 3

Completed

Conditions: Carcinoma, Squamous Cell of the Head and Neck

Interventions: Biological: REOLYSIN
Drug: Carboplatin
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2010-07-21

Last Posted Date: 2014-11-05

Lead Sponsor: Oncolytics Biotech

Target Recruit Count: 167

Registration Number: NCT01166542

Locations: 🇺🇸
Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸
Wilshire Oncology Medical Group, Corona, California, United States
🇺🇸
Pasco Hernando Oncology Associates, PA, New Port Richey, Florida, United States

and more 74 locations

Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Ipilimumab, 3 mg
Drug: Ipilimumab, 10 mg
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2010-07-19

Last Posted Date: 2014-07-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 15

Registration Number: NCT01165216

Locations: 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan

Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Hodgkin Lymphoma

Phase 1

Completed

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma

Interventions: Drug: Bendamustine Hydrochloride
Drug: Carboplatin
Biological: Rituximab
Drug: Etoposide
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-07-19

Last Posted Date: 2018-12-05

Lead Sponsor: University of Washington

Target Recruit Count: 48

Registration Number: NCT01165112

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2

Active, not recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Docetaxel
Drug: Cetuximab
Drug: Cisplatin
Radiation: Radiotherapy (RT)
Drug: Fluorouracil
Other: Chemotherapy

First Posted Date: 2010-07-01

Last Posted Date: 2024-12-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 128

Registration Number: NCT01154920

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Phase 2

Terminated

Conditions: Cholangiocarcinoma
Hepatobiliary Neoplasm
Liver Cancer
Bile Duct Cancer
Cancer of Gallbladder

Interventions: Procedure: Stereotactic Body Radiotherapy
Drug: Gemcitabine
Drug: Cisplatin
Drug: Carboplatin
Drug: Capecitabine
Drug: 5FU
Procedure: Liver transplantation

First Posted Date: 2010-06-28

Last Posted Date: 2016-07-29

Lead Sponsor: Stanford University

Target Recruit Count: 2

Registration Number: NCT01151761

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer

Phase 2

Completed

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Breast Carcinoma
Metastatic Breast Carcinoma
Unresectable Breast Carcinoma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Veliparib

First Posted Date: 2010-06-23

Last Posted Date: 2024-11-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT01149083

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 20 locations

Neoadjuvant Therapy for Ovarian Cancer

Phase 2

Completed

Conditions: Epithelial Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel
Drug: Bevacizumab

First Posted Date: 2010-06-22

Last Posted Date: 2021-02-09

Lead Sponsor: Jason D. Wright

Target Recruit Count: 32

Registration Number: NCT01146795

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States

WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer

Not Applicable

Terminated

Conditions: Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Carcinoma

Interventions: Drug: Hyperthermic intraperitoneal chemotherapy with Carboplatin
Other: Isotonic saline (perfusate)
Procedure: Surgery
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-06-15

Last Posted Date: 2019-07-30

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 10

Registration Number: NCT01144442

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Lenvatinib
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2010-05-31

Last Posted Date: 2023-06-22

Lead Sponsor: Eisai Inc.

Target Recruit Count: 7

Registration Number: NCT01133756

Locations: 🇺🇸
Texas Oncology - Austin Central, Austin, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy